TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02982252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoPILOT
Description: Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoPILOT
Description: Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
Study: NCT03181880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium bromide/formoterol fumarate combination
Description: Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Brochodilators
Study: NCT04659980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hilotherapy
Description: continuous cooling of hands and feet at a constant temperature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: frozen gloves
Description: cooling of hands and feet using frozen gloves
Study: NCT04394949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center for Independent Living SEEKS Team
Description: Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Consumers will get same CIL services they would get if they were not enrolled in the study.
Study: NCT00764660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900435
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study: NCT03053037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final apical size instrumentation
Description: root canal instrumentation to two different final preparation sizes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: final apical size instrumentation
Description: root canal instrumentation to two different final preparation sizes
Study: NCT01866462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NM504
Description: NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
Study: NCT03524417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine rabies immunoglobulin injection on day 7
Description: The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
Study: NCT00203619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy
Description: wire less capsule endoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard diagnostic evaluation as decided by treating physician
Study: NCT00885404

Intervention type: DRUG
Group type: OTHER
Intervention: Lower chloride fluids (Hartmann's solution and Plasmalyte®)
Description: Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
Study: NCT04674358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Opthalmic Solution
Description: Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).
Study: NCT03774186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop therapy
Description: Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-augmented pump therapy
Description: Insulin pump + non-communicating CGM
Study: NCT05414396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend EML program sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04192994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Antibiotic Injection
Description: Intravitreal Antibiotic Injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars Plana Vitrectomy
Description: Pars Plana Vitrectomy
Study: NCT04014660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo supplement consists of corn starch only.
Study: NCT03231813

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sodium lauryl sulphate induced irritation
Description: Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate induced irritation
Description: Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient, moisturizing cream
Description: Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Emollient, moisturizing cream
Description: Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
Study: NCT05214690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-T2
Description: pelubiprofen 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-T2
Description: pelubiprofen 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-1
Description: pelubiprofen 30mg (PELUBI tab.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-1
Description: pelubiprofen 30mg (PELUBI tab.)
Study: NCT01276756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Pegylated interferon 160ug once weekly 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Pegylated interferon 160ug once weekly 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
Study: NCT01992627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILTERAPIA HIRO 3.0
Description: High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
Study: NCT04291287

Intervention type: DRUG
Intervention: Antithrombotic Agent
Description: Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)

Intervention type: DRUG
Intervention: Antithrombotic Agent
Description: Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)
Study: NCT01045811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: Respiratory sinus arrhythmia biofeedback-assisted deep breathing training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management
Description: Cognitive reconstructive strategies for stress management
Study: NCT04544241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Survivorship Leadership Training for Clergy Wives and Widows
Description: We will meet with Clergy Wives and Widows monthly for 2-3 hours over 10 months. These sessions will be delivered using innovative online format through Zoom over the ten months. During each meeting session, experienced community and academic leaders will present their expertise with relationship to cancer survivorship and caregiving. These individuals will have extensive experience in the particular area they are presenting in. In addition, allotted time will be given for discussion and group activities that can be performed virtually. To receive credit for completion of the training program, each participant must complete the training and deliver a group workshop. All clergy wives and widows will complete a demographic questionnaire, in addition to pre- and post- intervention questionnaires
Study: NCT04653181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Iron-arm treated with Ferric carboxymaltose, non-iron arm without
Study: NCT00314340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity
Description: The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
Study: NCT05515159

Intervention type: OTHER
Intervention: electroconvulsive therapy
Description: electrical stimulation of the brain while the patient is under anesthesia.
Study: NCT00709280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% Hypertonic Saline (HS)
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Study: NCT00314340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity
Description: The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity
Description: The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
Study: NCT00709280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Isotonic Saline (IS)
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Study: NCT00314340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone plus acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00607620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
Study: NCT04066114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lulizumab pegol
Description: 25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin (rabbit)
Description: Study participants are administered four doses of rabbit anti-thymocyte globulin, total dose 6 mg/kg given in divided doses on the day of transplantation and days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
Study: NCT01182012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
Study: NCT04070001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 Mg Ibuprofen
Description: 1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser application
Description: A single irradiation of laser after elastomeric separator placement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: Placebo lactose tablets 1-hour before elastomeric separator placement
Study: NCT03353714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal block
Description: Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pudendal block
Description: Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
Study: NCT00997373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
Study: NCT01501539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Hydrocolloid Dressing
Description: Treatment placed over insertion site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silver Hydrocolloid Dressing
Description: Place dressing against skin under gastrostomy tube
Study: NCT05067608

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm receiving normal (never before frozen) platelets as per current clinical practice
Description: Liquid platelets arm (control) and may receive multiple platelet transfusions per thrombocytopenic cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment arm receiving cryopreserved platelets
Description: Cryopreserved platelets arm (treatment) and may receive multiple platelet transfusions per thrombocytopenic cycle.
Study: NCT00758901

Intervention type: DEVICE
Intervention: Knee Replacement (with ROCC Knee prosthesis)
Description: Knee Replacement (with ROCC Knee prosthesis)
Study: NCT02819037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gas chromatography
Study: NCT04066114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: 8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Beginning on Day 3 post transplantation, taken orally: 60 mg daily~* Days 4 through 10: 30 mg daily~* Days 11 through 17: 20 mg daily~* Days 18 through 24: 10 mg daily~* After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: 5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: mycophenolate mofetil is started no later than one day after transplant at 1000mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do no tolerate everolimus can stay on or switch back to mycophenolate mofetil 1000 mg twice daily and remain in trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolic acid
Description: mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
Study: NCT00728819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered PICC
Description: Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-tapered PICC
Description: Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
Study: NCT02819037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stool analysis for detection of malabsorption
Study: NCT00765336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline extended release
Description: 1 mg/kg extended release minocycline HCL, once daily for 84 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
Study: NCT03111680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: environmental intervention
Description: a multi component environmental intervention
Study: NCT03852472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Active treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01056783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: OC000459 100mg, twice daily, tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match OC000459 tablets, twice daily
Study: NCT03422068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: Tablet formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet formulation
Study: NCT00410813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: given orally
Study: NCT01417247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic modification
Description: Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
Study: NCT00216580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone, long-acting injectable
Study: NCT01742130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Study: NCT01534338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.